Pharmafit Provence

PARI France

PARI LC SPRINT SP Nebulizer with adult mask

CIP / EAN code: 3401046504854

Product information from VIDAL.

Read the product information
Back to the catalogue

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Parapharmacy
Update of 30/09/2026

CE PARI LC SPRINT® SP
nebulizers

Presentation 

Nebulizers with double venturi (increase the aerosol output produced during the patient's inspiration).
To be used with a PARI BOY compressor (SX or Pro).

Properties 

  • Economizer valves reducing the waste of the nebulized product during expirations.
  • Nebulizers intended to be used by a single patient.
Characteristics of the aerosol produced:
 
PARI LC SPRINT SP nebulizers:
  • Aerosol output rate: 0,16 ml/min.
  • Mass median aerodynamic diameter of particles (MMAD): 3,8 µm.
  • Respirable fraction (% particles < 5 µm): 61,9 %.
  • Quantity of aerosol produced: 0,41 ml.
PARI LC SPRINT SP BABY nebulizer:
  • Aerosol output rate: 0,10 ml/min.
  • Mass median aerodynamic diameter of particles (MMAD): 2,8 µm.
  • Respirable fraction (% particles < 5 µm): 80 %.
  • Quantity of aerosol produced: 0,35 ml.
Measurements performed with the PARI BOY Pro France compressor for 2,5 ml of salbutamol according to ISO standard 27427.

ADMINISTRATIVE INFORMATION 

Other references of the PARI LC SPRINT SP nebulizer:
  • PARI LC SPRINT SP nebulizer, with mouthpiece: 23G6110 (ACL 3401046504793/EAN 4251855901202).
  • PARI LC SPRINT SP nebulizer, with child mask: 23G6120 (ACL 3401046504915/EAN 4251855902322).
  • PARI LC SPRINT SP nebulizer, with adult mask: 23G6130 (ACL 3401046504854/EAN 4251855902834).
  • PARI LC SPRINT SP BABY nebulizer, with elbow and baby mask: 23G6150 (ACL 3401051600855/EAN 4251855902872).

ADMINISTRATIVE INFORMATION 

LPPR rate:
Maximum public sale price:12,93 euros incl. VAT (nebulizer purchase); LPPR codes 1172306 (ref. 23G6110/23G6120/23G6130), 1144652 (ref. 23G6150).
 
Indication for coverage:
Aerosol therapy by nebulization in the treatment of respiratory conditions and cystic fibrosis:
- for the administration of medicines that have received marketing authorization for this route of administration and, where applicable, according to the prescription conditions of the medicine defined by the marketing authorization;
- or for the administration of medical devices intended for nebulization listed on the list of products and services mentioned in article L. 165-1 of the Social Security Code and, where applicable, according to the prescription conditions defined for the medical device.

Medical device class IIa. CE marking 0123.

PARI FRANCE
51, Sainte-Anne street. 75002 Paris
Tel: 01 56 83 85 00
www.pari.com

Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.